Off-label mesenchymal stromal cell treatment in two infants with severe bronchopulmonary dysplasia: clinical course and biomarkers profile

Highlights • First report of intravenous administration of MSCs in preterm babies. • First report of the use of repeated, multiple doses of MSCs in human preterm babies. • Histopathological proof of the absence of engraftment of MSCs in the recipient lung. • Proof of the lack of toxicity in patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cytotherapy (Oxford, England) England), 2018-11, Vol.20 (11), p.1337-1344
Hauptverfasser:	Álvarez-Fuente, María, Arruza, Luis, Lopez-Ortego, Paloma, Moreno, Laura, Ramírez-Orellana, Manuel, Labrandero, Carlos, González, África, Melen, Gustavo, Cerro, Maria Jesús Del
Format:	Artikel
Sprache:	eng
Schlagworte:	Advanced Basic Science bronchopulmonary dysplasia chronic lung disease of the newborn mesenchymal stromal cells molecular biomarkers Other preterm newborns pulmonary vascular disease regenerative medicine very low–birth weight infants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • First report of intravenous administration of MSCs in preterm babies. • First report of the use of repeated, multiple doses of MSCs in human preterm babies. • Histopathological proof of the absence of engraftment of MSCs in the recipient lung. • Proof of the lack of toxicity in patients with severe BPD.
ISSN:	1465-3249 1477-2566
DOI:	10.1016/j.jcyt.2018.09.003